• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名患有亨特综合征的年轻成年人的皮质下梗死。

Subcortical infarction in a young adult with Hunter syndrome.

作者信息

Kimura Motoya, Azuma Yoshiteru, Taguchi Soutarou, Takagi Mizuki, Mori Hiromitsu, Shimomura Yasuto, Niwa Jun-Ichi, Doyu Manabu, Okumura Akihisa

机构信息

Department of Pediatrics, Aichi Medical University, Nagakute, Japan; Department of Neurology, Aichi Medical University, Nagakute, Japan.

Department of Pediatrics, Aichi Medical University, Nagakute, Japan.

出版信息

Brain Dev. 2022 May;44(5):343-346. doi: 10.1016/j.braindev.2022.01.003. Epub 2022 Feb 4.

DOI:10.1016/j.braindev.2022.01.003
PMID:35125232
Abstract

INTRODUCTION

Hunter syndrome (mucopolysaccharidosis type II, MPS II) is an X-linked lysosomal storage disease caused by deficiency of iduronate-2-sulfatase. Recently, stroke caused by embolization with Hunter syndrome has been reported. Here, we report the case of a 23-year-old Japanese man with Hunter syndrome who developed subcortical infarction by the mechanism similar to branch atheromatous disease (BAD).

CASE PRESENTATION

He had been treated with idursulfase supplementation. He presented with left-sided weakness and conjugate eye deviation to the right, and was diagnosed with branch atheromatous disease affecting the right corona radiata, based on MRI findings. The patient was treated with argatroban and aspirin. Magnetic resonance angiography demonstrated no evidence of luminal narrowing of the cerebral arteries. T1-sampling perfection with application-optimized contrasts by using different flip angle evolutions (SPACE) imaging revealed thickened middle cerebral artery. The patient had markedly low flow-mediated vasodilation, suggesting impaired vasodilation in response to nitric monoxide.

CONCLUSION

The arterial wall thickening and impaired vasodilation in the cerebral arteries related to subcortical infarction. We should clarify the mechanism of cerebral infarction in Hunter syndrome patients.

摘要

引言

亨特综合征(黏多糖贮积症II型,MPS II)是一种由艾杜糖醛酸-2-硫酸酯酶缺乏引起的X连锁溶酶体贮积病。最近,有报道称亨特综合征导致栓塞引起中风。在此,我们报告一例23岁日本男性亨特综合征患者,其发生皮质下梗死的机制类似于分支动脉粥样硬化病(BAD)。

病例介绍

他接受了艾杜糖醛酸酶补充治疗。他出现左侧肢体无力和双眼向右侧共轭偏斜,根据MRI检查结果被诊断为影响右侧放射冠的分支动脉粥样硬化病。患者接受了阿加曲班和阿司匹林治疗。磁共振血管造影未显示脑动脉管腔狭窄的证据。使用不同翻转角演变的应用优化对比的T1采样完美成像(SPACE)显示大脑中动脉增厚。患者的血流介导的血管舒张明显降低,提示对一氧化氮的血管舒张反应受损。

结论

与皮质下梗死相关的脑动脉壁增厚和血管舒张受损。我们应阐明亨特综合征患者脑梗死的机制。

相似文献

1
Subcortical infarction in a young adult with Hunter syndrome.一名患有亨特综合征的年轻成年人的皮质下梗死。
Brain Dev. 2022 May;44(5):343-346. doi: 10.1016/j.braindev.2022.01.003. Epub 2022 Feb 4.
2
First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).西班牙5岁以下亨特综合征患者使用艾度硫酸酯酶进行酶替代治疗的首次经验:来自亨特结果调查(HOS)的病例观察
Eur J Med Genet. 2010 Nov-Dec;53(6):371-7. doi: 10.1016/j.ejmg.2010.07.013. Epub 2010 Aug 10.
3
Cerebral infarction in Hunter syndrome.亨特综合征中的脑梗死
J Clin Neurosci. 2006 Dec;13(10):1054-7. doi: 10.1016/j.jocn.2005.12.038. Epub 2006 Oct 23.
4
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).用艾度硫酸酯酶进行酶替代疗法治疗II型黏多糖贮积症(亨特综合征)。
Cochrane Database Syst Rev. 2011 Nov 9(11):CD008185. doi: 10.1002/14651858.CD008185.pub2.
5
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).艾度硫酸酯酶用于黏多糖贮积症II型(亨特综合征)的酶替代疗法。
Cochrane Database Syst Rev. 2014 Jan 8(1):CD008185. doi: 10.1002/14651858.CD008185.pub3.
6
Expanding the phenotype of mucopolysaccharidosis type II retinopathy.扩大黏多糖贮积症 II 型视网膜病变的表型。
Ophthalmic Genet. 2021 Oct;42(5):631-636. doi: 10.1080/13816810.2021.1938141. Epub 2021 Jul 12.
7
Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.艾度硫酸酯酶治疗黏多糖贮积症II型(亨特综合征)的发展:过去、现在与未来。
Drug Des Devel Ther. 2017 Aug 23;11:2467-2480. doi: 10.2147/DDDT.S139601. eCollection 2017.
8
Hunter syndrome with late age of presentation: clinical description of a case and review of the literature.迟发型亨特综合征:一例临床描述及文献复习
BMJ Case Rep. 2015 May 14;2015:bcr2015209305. doi: 10.1136/bcr-2015-209305.
9
Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS).依鲁司他治疗黏多糖贮积症 II 型患者的临床结局:亨特结局调查(HOS)的 3 年数据。
Orphanet J Rare Dis. 2017 Oct 3;12(1):161. doi: 10.1186/s13023-017-0712-3.
10
Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).伊杜硫酸酯酶β治疗黏多糖贮积症 II 型(亨特综合征)患者的 I/II 期临床试验。
Orphanet J Rare Dis. 2013 Mar 18;8:42. doi: 10.1186/1750-1172-8-42.

引用本文的文献

1
Evaluation of the Utility of Hybrid PET/MR Neuroimaging in Inflammatory Demyelination and Encephalitis.PET/MR 混合神经成像在炎症性脱髓鞘疾病和脑炎中的应用评估
J Clin Med. 2025 Apr 16;14(8):2736. doi: 10.3390/jcm14082736.
2
Clinical and neuroimaging review of monogenic cerebral small vessel disease from the prenatal to adolescent developmental stage.从产前到青少年发育期的单基因脑小血管病的临床和神经影像学研究。
Jpn J Radiol. 2024 Feb;42(2):109-125. doi: 10.1007/s11604-023-01493-0. Epub 2023 Oct 17.